QWQiang Wang

Qiang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qiang Wang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Boyuan Chen

    Shanghai Immune Therapy Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Chong Liu

    Department of Neurosurgery of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    1 shared publication
  • Coco Chu

    Institute for Immunology, Tsinghua University, Beijing, China

    1 shared publication
  • Gregory F. Sonnenberg

    Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA.

    1 shared publication
  • Hongzhi Liu

    Shanghai Immune Therapy Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Hua Tang

    Institute of Infection and Immunity, Medical Science and Technology Innovation Center, Shandong First Medical University, Jinan, Shandong, China

    1 shared publication

Latest Publications

  • Fibroblasts restrain gut inflammation by IGF1-dependent regulation of innate lymphocytes

    by Qingxia Lin, Ruichao E. Liu, Qiang Wang, Lan Kang, Boyuan Chen, Yu Lu, Yanting Zhang, Zhijie Gu, Yu Zhou, Hongzhi Liu, et al.

    Fibroblasts exhibit phenotypic and functional heterogeneity in chronic inflammatory diseases, but how these changes impact immune outcomes remains poorly understood. We identified that a fibroblast population expressing insulin-like growth factor 1 (IGF1) was reduced in patients with inflammatory bowel disease (IBD). Using mouse models of intestinal inflammation, we found cross-talk between IGF1-expressing fibroblasts and group 3 innate lymphoid cells (ILC3s). IGF1 stimulation limited the ability of ILC3s to produce C-X-C motif chemokine ligand 10 (CXCL10) and recruit plasmacytoid dendritic cells (pDCs) to restrain gut inflammation. We propose that this regulatory pathway is conserved in human ILC3s but may become impaired in IBD. Our results define that anti-inflammatory fibroblasts safeguard the gut through regulation of an innate lymphocyte–pDC axis.